 | | Anno I – Numero 8 | Comitato scientifico editoriale: Giuseppe Curigliano, Alessandra Fabi, Matteo Lambertini
Editore: Intermedia, Direttore Responsabile: Mauro Boldrini | | | | Pubblicazioni recenti |
Axillary Surgery in Breast Cancer – Primary Results of the INSEMA Trial
Background: Whether surgical axillary staging as part of breast-conserving therapy can be omitted without compromising survival has remained unclear. Methods: In this prospective, randomized, noninferiority trial, we investigated the omission of axillary surgery as compared with sentinel-lymph-node biopsy in patients with clinically node-negative invasive breast cancer staged as T1 or T2 (tumor size, ≤5 cm) who were scheduled to undergo breast-conserving surgery … Continua a leggere
| Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Background: Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα (ESR1). Methods: In a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer that recurred or progressed during or after aromatase inhibitor therapy … Continua a leggere
|
Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer
Background: About 15-20 % of patients with metastatic breast cancer (mBC) can experience oligoprogressive disease (OPD) in ≤ 5 sites of disease. Patients with OPD may benefit from metastasis-directed stereotactic radiotherapy (SBRT) to all sites of cancer progression while maintaining the same systemic treatment, aiming to prolong the time to next systemic treatment (NEST). This study aims to assess the outcomes provided by this multimodal … Continua a leggere
| Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial
Optimal therapy following breast-conserving surgery in older adults with low-risk, early-stage breast cancer remains uncertain. The EUROPA trial aims to compare the effects of radiotherapy and endocrine therapy as single-modality treatments on health-related quality of life (HRQOL) and ipsilateral breast tumour recurrence (IBTR) outcomes in this population … Continua a leggere
|
Prognosis prediction with the IHC3 score in patients with node-negative, hormone receptor-positive, HER2-negative early breast cancer
Background: Prognostication has been used to identify patient populations that could potentially benefit from treatment de-escalation. In patients with hormone receptor-positive (HRpos), human epidermal growth factor receptor 2-negative (HER2neg) early breast cancer (eBC), treatment de-escalation classically involved omitting chemotherapy. With recently developed specialized therapies that require hands-on side-effect management … Continua a leggere
| | Videopillola |
Le linee guida AIOM sul trattamento del mTNBC | Fabio Puglisi
Clicca qui per vedere la videointervista
| | Appuntamenti | IX Corso Europeo di Psico-Oncologia
FAD, novembre 2024 – maggio 2025
Breast Cancer: Challenges and Advances in Supportive Care
I mercoledì dell’oncologia
Webinar NON ECM, 8 gennaio 2025 dalle 17.00 alle 18.15
Back from San Antonio
Genova, 10 – 11 gennaio 2025
Real world data and shared decision making: Navigating the intersection of quality, cost and survival
FAD, 13 gennaio 2025
Approccio Multidisciplinare al Tumore della Prostata
Acquaviva Delle Fonti (Ba), 14-15 Gennaio
GIST AVANZATI: IL VALORE DELLA GESTIONE MULTIDISCIPLINARE DEL PAZIENTE
Verona, 15 gennaio 2025
Breaking News sulle Terapie di Supporto in Oncologia
I mercoledì dell’oncologia
Webinar NON ECM, 22 gennaio 2025 dalle 17.00 alle 18.15
BREAKING NEWS IN BREAST CANCER
Convegno regionale AIOM Lazio
Roma, 27 gennaio 2025
I percorsi diagnostico terapeutici e assistenziali (PDTA): muoversi tra assistenza, risorse e rete regionale
Convegno regionale AIOM Emilia-Romagna
Bologna, 6 febbraio 2025
XXII Conferenza Nazionale AIOM
STUDI DI FASE I
Torino, 28 febbraio – 1° marzo 2025
CORSO DI RICERCA CLINICA ASCO-AIOM (ICRC)
III edizione
Roma, 14 – 15 marzo 2025
Infermieri e Medici: insieme per l’evoluzione dell’oncologia
Convegno regionale AIOM Liguria
Genova, 29 marzo 2025
Questi e altri appuntamenti si possono consultare sul sito AIOM: aiom.it
| © 2023 Editore: Intermedia srl Via Lunga 16a Brescia, BS 25124 Italy
tel. 030 226105 – 3888896214 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001
Iscrizione al Registro degli Operatori di Comunicazione N. 4867
Per contattare la redazione e commentare le notizie clicca qui
Ricevi questa email perché sei iscritto alla newsletter AIOM Cancellati
Privacy
Realizzata con il contributo non condizionante di
|
|
|
|
|